Prakt. lékáren. 2008; 4(4): 172-176

Psychofarmaka v léčbě schizofrenie

MUDr. Sylva Racková, MUDr. Luboš Janů Ph.D
Psychiatrická klinika FN a LF UK v Plzni

Schizofrenie je závažné psychické onemocnění se začátkem v mladém věku. V léčbě schizofrenie jsou rozhodující antipsychotika. V posledních letech jsou častěji užívána antipsychotika II. generace pro jejich lepší snášenlivost při zachovaném antipsychotickém efektu. Léčba antipsychotiky je dlouhodobá, proto je důležitý správný výběr typu a dávky preparátu a dostatečná edukace pacienta pro zlepšení spolupráce.

Keywords: Klíčová slova: schizofrenie, compliance, léčba, antipsychotika.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S, Janů L. Psychofarmaka v léčbě schizofrenie. Praktické lékárenství. 2008;4(4):172-176.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahnag-Wong J, Zipursky RB, Beiser M, Bean G. Optimal haloperidol dosage for first-episode psychosis. Can J Psychiatry 1999; 44: 164-167. Go to original source... Go to PubMed...
    2. APA (American Psychiatric Assotiation): Practice guidelines for the treatment of psychiatric disorders, Schizophrenia. Compendium, 2004.
    3. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 1990; 41: 1203-1211. Go to original source... Go to PubMed...
    4. Češková E, Tůma I, Přikryl R, Pěč O. Psychiatrie, doporučené postupy psychiatrické péče II. Infopharm 2006; 54-61.
    5. Češková E. Nové trendy v léčbě schizofrenie. Psychiatr. pro praxi 2008; 9(1): 40-43.
    6. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-565. Go to original source... Go to PubMed...
    7. García-Cabeza I, Gómez JC, Sakristán JA, Edgell E, Chavez MG. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry 2001; 1: 7-14. Go to original source... Go to PubMed...
    8. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376. Go to original source... Go to PubMed...
    9. Gerlach J. Improving Outcome in Schizophrenia: The Potential Importace of EPS and Neuroleptic Dysphoria. Ann Clin Psychiatry 2002; 14(1): 47-57. Go to original source...
    10. Haan L, Lavalaye J, Bruggen M, Nimwegen L, Booij J, Amelsvoort T, Linszen D. Subjective Experience and Dopamine D2 Receptor Occupancy in Patiens Treated With Antipsychotics: Clinical Implications. Can J Psychiatry 2004; 49: 290-296. Go to original source... Go to PubMed...
    11. Haan L, Lavalaye J, Linszen D, Dingemans PMAJ, Booij J. Subjective Experience and Striatal Dopamine D2 Receptor Occupancy in Patiens with Schizophrenia Stabilized by Olanzapine or Risperidone. Am J Psychiatry 2000; 157: 1019-1020. Go to original source... Go to PubMed...
    12. Hoschl C, Libiger J, Švestka J. Libiger J. Schizofrenní poruchy. Psychiatrie: Tigis, 2002: 342-400.
    13. Hoschl C, Libiger J, Švestka J. Švestka J. Antipsychotika. Psychiatrie: Tigis, 2002: 692-704.
    14. Kaplan HI, Sadock BJ. Concise textbook of clinical psychiatry. Philadelphia: Williams and Wilkins, 1996; 669.
    15. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry, 2003; 27: 1081-1090. Go to original source... Go to PubMed...
    16. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased Dopamine D2 Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidole to Clozapine. Am J Psychiatry 2001; 158: 311-314. Go to original source... Go to PubMed...
    17. Kapur S, Seeman P. Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis. Am J Psychiatry 2001; 158: 360-369. Go to original source... Go to PubMed...
    18. Kapur S, Zipursky RB, Remington B. Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia. Am J Psychiatry 1999; 156: 286-293. Go to original source... Go to PubMed...
    19. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double Blind PET Study of First-Episode Schizophrenia. Am J Psychiatry 2000; 157: 514-520. Go to original source... Go to PubMed...
    20. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. 5-HT2 and D2 Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation. Am J Psychiatry 1998; 155: 921-928. Go to original source... Go to PubMed...
    21. Kerwin R, Millet B, Herman E. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of communitytreated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study. European Psychiatry 2007; 433-443. Go to original source... Go to PubMed...
    22. Kissling W, Leucht S. Results of treatment of schizophrenia: Is the glass half full or half empty? Int Clin Psychopharmacology 1999; 14(Suppl 3): S11-S14. Go to original source... Go to PubMed...
    23. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48: 739-745. Go to original source... Go to PubMed...
    24. Raboch J, Zvolský P, Libiger J. Schizofrenie, Psychiatrie. Praha: Galén, 2001: 227-226.
    25. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response froma first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247. Go to original source... Go to PubMed...
    26. Seifertová D, Praško J, Höschl C. Postupy v léčbě psychických poruch, Schizofrenie. Academia medica pragensis 2004; 47-63.
    27. Švestka J a kol. Psychofarmaka v klinické praxi. Praha: Grada, 1995; 149-175.
    28. Voruganti L, Awad AG. Is Neuroleptic Dysphoria a Variant of Drug-Induced Extrapyramidal Side Effects? Can J Psychiatry 2004; 49: 285-289. Go to original source... Go to PubMed...
    29. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology 2004; 171(2): 121-132. Go to original source... Go to PubMed...
    30. Zisook S, McAdams L, Kuck J, Hartus J, Bailey A, Patterson TL, Judd LL, Jeste DV. Depressive Symptoms in Schizophrenia. Am J Psychiatry 1999; 156: 1736-1743. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.